# A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

> **NCT06682572** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Verastem, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Low Grade Serous Ovarian Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Avutometinib (VS-6766) + Defactinib (VS-6063)

## Key facts

- **NCT ID:** NCT06682572
- **Lead sponsor:** Verastem, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2025-12
- **Final completion:** 2027-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682572, "A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06682572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*